- IN₹238.17bn
- IN₹258.83bn
- IN₹60.41bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 54.96 | ||
| PEG Ratio (f) | 1.02 | ||
| EPS Growth (f) | 117.41% | ||
| Dividend Yield (f) | 0.31% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.91 | ||
| Price to Tang. Book | 6.32 | ||
| Price to Free Cashflow | 82.97 | ||
| Price to Sales | 4.78 | ||
| EV to EBITDA | 31.5 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 8.85% | ||
| Return on Equity | 4.82% | ||
| Operating Margin | 9.08% | ||
Financial Summary
| Year End 31st Mar | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 22,919.16 | 28,317.23 | 48,135.1 | 49,355.7 | 60,405.5 | 50,642.55 | 58,485.76 | 23.9% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -44.29 | +172.58 | +281.17 | -15.97 | -4.69 | -74.75 | +117.41 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Laurus Labs Limited is an India-based pharmaceutical and biotechnology company. The Company offers integrated portfolio of Active Pharma Ingredients (API) including intermediates, Generic Finished dosage forms (FDF) and Contract Research services to cater to the needs of the global pharmaceutical industry. The Company operates through three segments: Laurus Generics, Laurus Synthesis, and Laurus Bio. The Laurus Generics segment comprises API and FDF-Development, manufacture and sale of APIs and advanced intermediates and oral solid formulations/FDF. Laurus Synthesis segment comprises key starting materials (KSM), intermediates and APIs for new chemical entities (NCEs). Laurus Bio segment comprises recombinant products, animal origin free products for safer and viral free bio manufacturing. The Company operates through two geographical segments: Revenue from customers within India-Domestic, and Revenue from customers outside India-Exports. The Company sell its APIs in 56 countries.
Directors
- M.Venu Gopala Rao NEC
- Satyanarayana Chava CEO (55)
- Ravikumar V CFO (51)
- GSR Anjaneyulu EVP
- V. Uma Maheswer Rao EVP
- M. Bhaskaraiah SVP
- Martyn James Peck SVP
- Srinivasa S SVP
- Lakshmana V SVP
- G. Venkateswar Reddy GMG
- Chandrakanth Chereddi EDR (34)
- Venkata Chunduru EDR
- Aruna Bhinge NID (59)
- Rajesh Chandy NID (47)
- Ravindranath Kancherla NID
- Last Annual
- March 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- September 19th, 2005
- Public Since
- December 19th, 2016
- No. of Shareholders
- 418,615
- No. of Employees
- 5,753
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
National Stock Exchange of India- Shares in Issue
- 538,965,858
- Address
- Serene Chambers, Road No 7, Banjarahills, HYDERABAD, 500034
- Web
- http://www.lauruslabs.com/
- Phone
- +91 4039804333
- Contact
- G. Venkateswar Reddy
- Auditors
- Deloitte Haskins & Sells LLP
Upcoming Events for LAURUSLABS
Laurus Labs Ltd Annual Shareholders Meeting
Q1 2025 Laurus Labs Ltd Earnings Release
Similar to LAURUSLABS
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
What is the Laurus Labs share price?
As of Today at 19:13 UTC, shares in Laurus Labs are trading at IN₹441.90. This share price information is delayed by 15 minutes.
How has the Laurus Labs share price performed this year?
Shares in Laurus Labs last closed at IN₹441.90 and the price had moved by +40.78% over the past 365 days. In terms of relative price strength the Laurus Labs share price has outperformed the S&P BSE 100 Index by +6.69% over the past year.
What are the analyst and broker recommendations for Laurus Labs?
The overall consensus recommendation for Laurus Labs is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Laurus Labs dividend yield?
The Laurus Labs dividend yield is 0.36% based on the trailing twelve month period.
Does Laurus Labs pay a dividend?
Last year, Laurus Labs paid a total dividend of IN₹1.60, and it currently has a trailing dividend yield of 0.36%. We do not have any data on when Laurus Labs is to next pay dividends.
When does Laurus Labs next pay dividends?
We do not have data on when Laurus Labs is to next pay dividends. The historic dividend yield on Laurus Labs shares is currently 0.36%.
How do I buy Laurus Labs shares?
To buy shares in Laurus Labs you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Laurus Labs?
As of the previous close price of IN₹441.90, shares in Laurus Labs had a market capitalisation of IN₹238.17bn.
Where are Laurus Labs shares listed?
Here are the trading details for Laurus Labs:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: LAURUSLABS
What kind of share is Laurus Labs?
Based on an overall assessment of its quality, value and momentum Laurus Labs is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Laurus Labs share price forecast for 2024?
The analyst consensus target price for shares in Laurus Labs is IN₹358.83. That is 18.8% below the last closing price of IN₹441.90.
Analysts covering Laurus Labs currently have a consensus Earnings Per Share (EPS) forecast of IN₹3.70 for the next financial year.
What is the trend in the Laurus Labs share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Laurus Labs. Over the past six months, its share price has underperformed the S&P BSE 100 Index by -7.16%.
As of the last closing price of IN₹441.90, shares in Laurus Labs were trading +13.12% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Laurus Labs PE Ratio?
The Laurus Labs PE ratio based on its reported earnings over the past 12 months is 54.96. The shares last closed at IN₹441.90.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Laurus Labs?
Laurus Labs' management team is headed by:
- M.Venu Gopala Rao - NEC
- Satyanarayana Chava - CEO
- Ravikumar V - CFO
- GSR Anjaneyulu - EVP
- V. Uma Maheswer Rao - EVP
- M. Bhaskaraiah - SVP
- Martyn James Peck - SVP
- Srinivasa S - SVP
- Lakshmana V - SVP
- G. Venkateswar Reddy - GMG
- Chandrakanth Chereddi - EDR
- Venkata Chunduru - EDR
- Aruna Bhinge - NID
- Rajesh Chandy - NID
- Ravindranath Kancherla - NID